Skip to content

Stereotactic Radiotherapy for Fatal Arrhythmias

Stereotactic Radiotherapy for Fatal Arrhythmias

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs042230030
Enrollment
3
Registered
2023-06-02
Start date
2023-10-18
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ventricular tachycardia arrhythmia, cardiac, abblation, stereotactic radiotherapy, radioablation

Interventions

Stereotactic radiotherapy for VT origins
stereotactic body radiotherapy, VT radiotherapy

Sponsors

Kawamura Mariko
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) 18 years or older 2) After ICD implantation 3) Patients who have had a recurrence after more than 1 catheter ablation 4) Patients who have experienced 3 or more VT attacks within the past 3 months while taking at least 1 antiarrhythmic drug 5) Patients with fatal arrhythmia that cannot be cured by catheter ablation 6) Patients with no history of irradiation to the cardiac area 7) Patients with written consent from the patient

Exclusion criteria

Exclusion criteria: 1) Heart failure dependent on left ventricular assist device 2) Patients with low probability of survival for more than 6 months due to factors other than VT 3) Cases in which irradiation is contraindicated 4) Patients undergoing maintenance hemodialysis or peritoneal dialysis 5) Patients with heart disease requiring surgical treatment 6) Patients with acute coronary syndrome or acute heart failure requiring hospitalization 7) Patient is at high risk of radiation pneumonitis, such as idiopathic pulmonary fibrosis (IPF) on chest CT 8) Difficult-to-control pericardial effusions or pleural effusions 9) Difficulty in maintaining supine rest for 1 hour. 10) Other illnesses or reasons that make it difficult to perform necessary examinations or follow-up investigations, or for which the principal investigator/participating physician determines that the patient is not suitable to participate in this study.

Design outcomes

Primary

MeasureTime frame
Treatment safety in the early post-treatment period (within 1 year)

Secondary

MeasureTime frame
Treatment efficacy

Contacts

Public ContactMariko Kawamura

Nagoya University Hospital

mkawamura@med.nagoya-u.ac.jp+81-527442327

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026